| http://www.w3.org/ns/prov#value | - THURSDAY, Dec. 2 (HealthDay News) -- In a rat model of type 2 diabetes, treatment with the glucagon-like peptide-1 analog liraglutide delays the development of the disease due to factors such as lower energy intake and body weight and improved insulin sensitivity, according to research published in the October issue of Diabetes.
|
